Aurinia Pharmaceuticals (AUPH) Tops Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Aurinia Pharmaceuticals (AUPH) PT Raised to $9 at RBC Capital
November 11, 2024 6:20 AM ESTRBC Capital analyst Douglas Miehm raised the price target on Aurinia Pharmaceuticals (NASDAQ: AUPH) to $9.00 (from $8.00) while maintaining a Outperform rating.
The analyst comments "Aurinia's Q3/24 product revenues of $55.5MM (+36% y/y) were ~2% ahead of estimates. Management reiterated its 2024 LUPKYNIS net revenue... More
